AlphaCore Capital’s Cidara Therapeutics CDTX Stock Holding History

AlphaCore Capital’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-66,790	Closed	-$14.8M	–	1265
2025 Q4	$14.8M	Buy	+66,790	New	+$10.8M	0.33%	75

AlphaCore Capital's CDTX Position: Q1 2026 in Review

AlphaCore Capital sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 66,790 shares — an estimated $14.8M sold.

AlphaCore Capital first reported a position in CDTX in Q4 2025 and held it in 1 quarter. The position peaked at $14.8M in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.

AlphaCore Capital reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
AlphaCore Capital sold 66,790 Cidara Therapeutics shares in Q1 2026, an estimated $14.8M.
AlphaCore Capital first reported a position in Cidara Therapeutics in Q4 2025 and held it in 1 quarter.
AlphaCore Capital's Cidara Therapeutics position peaked at $14.8M in Q4 2025.
0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.

Based on AlphaCore Capital's 13F filing for Q1 2026, filed 15 May 2026.